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CLCN5 chloride-channel mutations in six new North American
families with X-linked nephrolithiasis.
Background. X-linked nephrolithiasis, or Dent’s disease, en-
compasses several clinical syndromes of low molecular weight
(LMW) proteinuria, hypercalciuria, nephrocalcinosis, nephroli-
thiasis, and renal failure, and is associated with mutations in the
CLCN5 gene encoding a kidney-specific voltage-gated chloride
channel. Some patients from Europe have rickets, and all symp-
tomatic patients confirmed by mutation analysis have been male.
Methods. We analyzed the CLCN5 DNA sequence in six new
families with this disease.
Results. In three probands, a single-base substitution yielded a
nonsense triplet at codons 28, 34, and 343, respectively, and in two
families, one of which was Hispanic, we found single-base dele-
tions at codons 40 and 44, leading to premature termination of
translation. In the sixth family, a single-base change from C to T
predicted substitution of leucine for serine at codon 244, previ-
ously reported in two European families with prominent rickets,
though this patient of Ashkenazi origin did not have rickets. Each
of these mutations was confirmed by restriction endonuclease
analysis, or repeat sequencing and CFLP. The R34X mutation
occurred in a Canadian infant with severe rickets. The family with
the R28X nonsense mutation included one woman with recurrent
kidney stones and another woman with glomerular sclerosis. In
another family, a woman heterozygous for the W343X mutation
also had nephrolithiasis.
Conclusions. These studies expand the range of mutations
identified in this disease, and broaden the phenotypic range to
include clinically affected women and the first North American
case with severe rickets.
Several syndromes of X-linked hypercalciuric nephroli-
thiasis have been reported that are associated with inacti-
vating mutations in the CLCN5 gene, which encodes a
voltage-gated chloride channel expressed in kidney [1–4].
X-linked recessive nephrolithiasis (XRN) [5, 6] and Dent’s
disease [7] share in common a number of findings including
low-molecular-weight (LMW) proteinuria, hypercalciuria,
calcium nephrolithiasis, nephrocalcinosis, and progressive
renal insufficiency. Asymptomatic Japanese schoolchildren
with LMW proteinuria, hypercalciuria, and nephrocalcino-
sis, identified through a nationwide screening program, also
have mutations in this gene [3, 8, 9]. Rickets was a
presenting feature in a third of affected males with Dent’s
disease [7] and in all nine affected males in two unrelated
families with “X-linked recessive hypophosphatemic rick-
ets” (XLRH) from Italy [10] and France [11] who also have
a mutation in the CLCN5 gene [2, 11], but in none of the 18
reported patients with XRN from North America [2, 4, 5,
12, 13]. Until now, all affected individuals confirmed by
mutation analysis have been male.
We studied ten affected males in six new families with
X-linked nephrolithiasis in North America, and have con-
firmed the presence of inactivating mutations in CLCN5 in
each of them. Prominent features in these affected individ-
uals include evidence of renal tubular dysfunction, partic-
ularly LMW proteinuria, as well as hypercalciuria, hema-
turia, nephrolithiasis or nephrocalcinosis, and progressive
renal insufficiency. These patients include the first reported
North American case with rickets. Furthermore, several
women in these families are the first affected females
documented to be heterozygous for a mutation in the
CLCN5 gene who have clinically significant disease. In
addition, one family shares the same mutation (S244L) that
was also reported in Italian and French patients with
X-linked recessive hypophosphatemic rickets, but this
North American patient had clinical renal disease and
stones without any evidence of rickets. Together these
Key words: X-linked nephrolithiasis, chloride channel, rickets, Dent’s
disease, kidney stones.
Received for publication November 17, 1997
and in revised form April 8, 1998
Accepted for publication April 14, 1998
© 1998 by the International Society of Nephrology
Kidney International, Vol. 54 (1998), pp. 698–705
698
cases illustrate the variety of clinical phenotypes associated
with mutations in CLCN5. They also provide additional
examples of overlap between the various clinical presenta-
tions that serve to reinforce the molecular evidence that
these syndromes are not separate and discreet, but rather
represent variations within a single disease entity.
METHODS
Patients
Patients were identified by their physicians as exhibiting
the clinical features of XRN or Dent’s disease, and all were
documented to have excessive excretion of LMW proteins,
particularly b2-microglobulin. Key clinical features of pa-
tients with symptomatic disease are summarized in Table 1.
Brief clinical summaries of the relevant cases follow.
Family A. Three males and two females in this family
have been documented to have clinically apparent disease
associated with mutations in CLCN5 (Figure 1). Several
additional male members of the pedigree are known to
have had nephrolithiasis or renal failure. While their
relationships to these confirmed patients are consistent
with X-linked inheritance, they were unavailable for study.
Patient A-II-2 (Fig. 1; male) was noted at age 7 to have
crystalluria. Evaluation at age 25 revealed renal insuffi-
ciency (serum creatinine 2.2 mg/dl), extensive medullary
nephrocalcinosis with multiple stones, and aminoaciduria.
The patient required hemodialysis at age 35, and bilateral
nephrectomies were performed. A first renal transplant
failed when immunosuppressive therapy was withheld be-
cause of a dramatic neurologic reaction to cyclosporine A,
for which his case was reported [14]. A second transplant
has functioned well for four years without recurrence of
nephrolithiasis. His brother, patient A-II-3, has recurrent
nephrolithiasis and LMW proteinuria. Their mother, pa-
tient A-I-2, at age 65 had chronic renal insufficiency (serum
creatinine 2.1 mg/dl), LMW proteinuria, and a renal biopsy
indicating glomerular sclerosis, interstitial inflammation
and tubular atrophy. She also has hypertension, which is
unusual in this disease.
Patient A-IV-1 presented at age four years with protein-
uria (34 mg/m2/hr) and hematuria. Serologic studies were
negative, and renal biopsy revealed glomerular sclerosis
with interstitial fibrosis and calcification. He has marked
LMW proteinuria, consistent with the degree in affected
males, and his mother (A-III-1), maternal grandmother
(A-II-1), and maternal great-grandmother (A-I-1) all have
moderate LMW proteinuria, consistent with the carrier
state [6]. That maternal great-grandmother (A-I-1) has also
had recurrent nephrolithiasis.
Family B. Aminoaciduria was detected by screening in
the affected boy at infancy. At age 2 he had hematuria,
proteinuria, hypercalciuria, renal phosphate wasting (tubu-
lar reabsorption of phosphate 72%), aminoaciduria, b2-
microglobulinuria, and active rickets. Serum levels of cal-
cium (2.47 mM) and phosphorus (1.74 mM) were normal,
and the level of 1,25-dihydroxyvitamin D was high (76
pg/ml). The rickets improved following supplementation
with vitamin D and phosphorus. Renal ultrasonography
indicated medullary nephrocalcinosis, and biopsy revealed
interstitial fibrosis, tubular atrophy, and some glomerular
sclerosis. Renal function deteriorated. Recently, at age 15,
serum PTH level was normal at 21 pg/ml (normal range 10
to 60 pg/ml) despite progressive renal insufficiency with
serum creatinine 1.35 mg/dl.
Family C. This boy presented at age 4 with microscopic
hematuria, proteinuria and nephrolithiasis. He has had
Table 1. Clinical features of affected males and females with X-linked nephrolithiasis (Dent’s disease)
Patient Age Sex Hypercalciuria Stones Nephrocalcinosis
PTH pg/ml
(nl 10–65)
1.25 (OH)2D
(nl 10–65 pg/ml) Other
A-II-2 46 male NA yes yes NA NA Aminoaciduria; ESRD
A-II-3 37 male NA yes no NA NA
A-I-2 65 female NA no no NA NA CCr 36 ml/min; hypertensive
A-I-1 80 female NA yes no NA NA
A-IV-1 6 male 8.4 mg/kg/24 hr no no 22 50a
B 15 male Ca/Cr 0.32–0.57 mg/mg no yes 21b 76c Rickets, phosphate-wasting;
serum creatinine 1.35 mg/dl
C-II-1 13 male Ca/Cr 0.38 mg/mg yes yes NA NA
C-I-1 35 female Ca/Cr 0.12 mg/mg yes no NA NA
D-II-1 54 male 590 mg/24 hr no yes NA NA Intermittent aminoaciduria;
hypokalemia; glycosuria; polyuria
D-II-2 49 male “hypercalciuric” yes yes NA NA Aminoaciduria; glycosuria; genu
valgum; ESRD; transplant
E-II-1 5 male 8 mg/kg/24 hr no yes 9 59 Hypouricemia; phosphaturia
E-II-2 2 male Ca/Cr 0.93–1.9 mg/mg yes yes 19 67.3
F 5 male 6 mg/kg/24 hr no yes 22 NA Aminoaciduria; CCr 71 ml/min/1.73 m
2
Abbreviations are: NA, not available; CCr, creatinine clearance; Ca/Cr, mg calcium/mg creatinine.
a nl 20–76 pg/ml
b age 15; serum creatinine 1.36 mg/dl
c at age 2 years
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persistent hypercalciuria and nephrocalcinosis, and mark-
edly excessive LMW proteinuria. With thiazide, urine
calcium/creatinine ratio fell from 0.38 to 0.02. Serum
calcium and phosphorus levels have been normal. The most
recent serum creatinine at age 13 was 1.1 mg/dl. His
brother is clinically normal, with normal excretion of LMW
proteins. Their mother is adopted and her family history is
unavailable. She has had nephrolithiasis.
Family D. This affected male (D-I-1) had polyuria and
nocturia from infancy. At age six years he was documented
at New York Hospital to have microscopic hematuria, 2.7
g/day of proteinuria, and hypophosphatemia (3.7 mg/dl). At
age 17 he was evaluated at the Toronto General Hospital
and documented to have nephrocalcinosis, hypercalciuria
(442 to 622 mg/day), aminoaciduria, renal glycosuria, mild
hypophosphatemia (2.6 mg/dl) and hypokalemia (3.5 mEq/
liter), and a serum creatinine of 1.9 mg/dl. Urinary acidi-
fying ability was normal (minimum urine pH 5.14). Hyper-
calciuria was exacerbated by a Na/K citrate preparation but
not by K/H citrate. His mother’s sister’s son (D-II-2) had
renal glycosuria, nonspecific aminoaciduria, phosphate
wasting, nephrolithiasis, nephrocalcinosis, and renal fail-
ure, and now has a successful kidney transplant. That
patient had asymptomatic radiographic evidence of bone
demineralization and mild genu valgum deformity, but
normal growth. The family history also included the mater-
nal grandfather with polyuria and renal disease, and a
maternal uncle with nephrolithiasis.
Family E. Patient E-II-1 presented at 16 months of age
with occult hematuria and proteinuria. Evaluation revealed
phosphaturia and hypouricemia with an increased frac-
tional urate clearance (23 to 25%). At age five years he had
hypercalciuria (8.5 mg/kg/day) and LMW proteinuria. His
younger brother (E-II-2) was evaluated at six months of age
because of the brother’s history, and was found to have
normal tubular function and a normal urinalysis, but fur-
ther studies at age two years indicated microhematuria,
severe hypercalciuria (Ca/Cr 1.9), proteinuria (1.8 g/24 hr),
marked b2-microglobulinuria, and mild nephrocalcinosis.
In both brothers, calcium excretion decreased on treatment
with hydrochlorothiazide. The mother excreted normal
amounts of b2-microglobulin. The family (of Hispanic
origin) included a maternal uncle with nephrolithiasis.
Family F. The 3-year-old male proband was noted inci-
dentally to have microscopic hematuria and proteinuria
(720 mg/day). Further evaluation revealed hypercalciuria
(5.6 to 6.4 mg/kg/24 hr), aminoaciduria, hyperuricosuria, a
reduced GFR, and marked b2-microglobulinuria. The boy
is now five years old and lacks any clinical or biochemical
evidence for bone disease. The family, of Ashkenazi Jewish
Fig. 1. Segregation of the R28X mutation in
Family A. The C-to-T base substitution disrupts
an XhoI recognition sequence. Thus, when
genomic DNA is amplified with exon-specific
primers and digested with XhoI, this results in a
product of 271 bp rather than the normal
product size of 228 bp. Heterozyous females
display both the mutant (m) and wild-type (wt)
alleles, affected males display the mutant allele,
and normal males the WT allele. This family
includes carrier females I-1, with symptomatic
recurrent nephrolithiasis, and I-2, with renal
insufficiency and proteinuria.
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origin, included the boy’s mother with LMW proteinuria
but otherwise normal renal function, the maternal grand-
father who had died at age 39 of renal failure with
proteinuria and calcific densities in the kidneys, that grand-
father’s brother who died at 33 years of age with renal
failure, and that granduncle’s daughter’s son who has had
recurrent nephrolithiasis and chronic renal failure without
rickets. This latter patient recently received a kidney trans-
plant from his mother (an obligate carrier).
Mutation analysis
Sequencing. Genomic DNA was extracted from periph-
eral leukocytes using a Puregene DNA Isolation Kit (Gen-
tra Systems, Inc.). The 11 exons comprising the open
reading frame were amplified by polymerase chain reaction
(PCR) using specific flanking intronic primers as described
by Lloyd et al [3]. The DNA sequence of all 746 codons was
determined using an automated Perkin Elmer/Applied
Biosystems Division 373A Stretch DNA sequencer with 48
cm well-to-read plates. Dye terminator chemistry was used
with AmpliTaq-FS DNA polymerase.
Restriction digestion and Cleavasey fragment length poly-
morphism (CFLP) assays. All six mutations identified by
DNA sequencing were confirmed by an independent
method. Four of the mutations either created or destroyed
a restriction endonuclease site. These mutations were
confirmed by PCR amplification of the relevant exon
followed by digestion of the PCR product with the appro-
priate restriction enzyme and electrophoresis on a 2%
agarose gel. Two other mutations neither created nor
destroyed any restriction sites and these mutations were
confirmed using the Cleavasey fragment length polymor-
phism (CFLP) assay (Third Wave Technologies, Inc; http://
www.twt.com). CFLP assays were performed according to
the manufacturer’s recommended protocol. Briefly, subject
genomic DNA was amplified by PCR, the PCR product
purified by extraction from a denaturing polyacrylamide
gel, the CFLP reactions carried out, and the products
analyzed by electrophoresis on a DNA sequencing gel.
Three hundred nanograms of sample genomic DNA, ex-
tracted as described above, were used as template in 100 ml
PCR amplification reactions, with 0.1 mM primers, 2.5 units
of Taq DNA polymerase (Perkin Elmer), 1x PCR buffer
(standard, provided with Taq), and 50 mM of each dNTP.
Amplification reactions were carried out for 42 cycles, with
30-second denaturations at 95°C, one-minute annealing
steps at 56°C, and one-minute extensions at 72°C. One of
each primer pair for the PCR reactions was end-labeled in
a 20 ml reaction, with 40 pmole primer, 34 pmole 32P-ATP,
40 units T4-polynucleotide kinase, using the provided ki-
nase buffer for 30 minutes at 37°C, followed by inactivation
at 90°C for five minutes. The 20 ml CFLP assay reactions
were carried out in the supplied buffer with 0.2 mM MnCl2,
using 59 end-labeled DNA at 100,000 cpm, and 25 units of
Cleavase I enzyme. The DNA template was heated to 95°C
for 20 seconds and then cooled to 45°C, before addition to
the reaction mix. Reactions were carried out for five
minutes at 45°C, and stopped with the addition of stop
buffer. Products were heated for two minutes at 80°C just
before loading onto a 6% denaturing sequencing gel.
RESULTS
The six mutations identified in these families are sum-
marized in Table 2. In three probands, a single-base
substitution yielded a nonsense triplet at codons 28, 34, and
343, respectively. The W343X mutation was previously
described in a Japanese kindred with LMW proteinuria,
hypercalciuria and nephrocalcinosis [3]. In two families,
one of which (E) was Hispanic, we found single-base
deletions at codons 40 and 44, leading to frameshifts with 7
or 3 missense amino acids, respectively, followed by pre-
mature termination of translation in both cases at codon 47.
In the sixth family, a single-base change from C to T led to
the substitution of leucine for serine at codon 244. The
same mutation has already been reported in an Italian
family and a French family in which rickets was prominent
[10, 11], though this patient (of Ashkenazi origin) did not
have rickets, nor did his affected male relatives.
Four of these mutations either created or disrupted a
restriction enzyme site, and all of these were confirmed by
restriction enzyme analysis. Figure 1 shows segregation of
the R28X mutation with clinical disease in multiple af-
fected individuals in family A, including one woman (A-I-1)
with recurrent kidney stones, another woman (A-I-2) with
glomerular sclerosis and renal insufficency, and several
males with typical clinical features of X-linked nephrolithi-
asis. Figure 2 illustrates segregation of the W343X non-
sense mutation with the disease in Family C, which includes
Table 2. Mutations identified in six new families with X-linked nephrolithiasis (Dent’s disease)
Family Codon Base change Amino acid change Restriction enzyme/CFLP
Nonsense
A 28 CGA3 TGA Arg3 Stop Xho I
B 34 CGA3 TGA Arg3 Stop Ban I
C 343 TGG3 TAG Trp3 Stop Bfa I
Frameshift
D 40 AGC3 2GC 7 missense aa and Stop CFLP
E 44 ACA3 AC2 3 missense aa and Stop Bsr I
Missense
F 244 TCG3 TTG Ser3 Leu CFLP
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a heterozygous woman with nephrolithiasis (C-I-1), and
also shows segregation of the codon 44 frameshift mutation
with disease in Family E. Figure 3 displays the electro-
pherogram documenting the C-to-T transition in patient B,
which was confirmed by restriction analysis using BanI (not
shown).
Two mutations did not disrupt or create a restriction
enzyme site, and these were confirmed using CFLP analysis
(Figure 4). The CFLP assay is based on the use of a
structure-specific endonuclease that cleaves single-
stranded DNA of specific conformations at the base of
stem and loop structures. These conformations can be
altered by a change in even a single base within 50 bp of the
cleavage site. Thus, the location of an abnormal band from
the exon being analyzed provides information about muta-
tion location, allowing identification of the mutation by
direct sequencing of a small region of the DNA. The CFLP
assay is reported to have a sensitivity greater than that of
SSCP for the detection of mutations, and comparable to
that of DNA sequencing, and it can be performed on much
longer regions of DNA sequence than SSCP (more than
2500 bps, compared to the 250 bp limit for SSCP) [15, 16].
In this study we used CFLP to confirm mutations that we
had identified by sequencing, and not to screen for muta-
tions, and so we cannot comment on its sensitivity in our
hands. We were able easily to confirm the mutations in
exons 3 and 7 in families D and F, respectively, for which no
restriction site was available for analysis, as well as confirm-
ing a mutation in family E, also in exon 3, which had
already been confirmed by restriction analysis (Fig. 4).
DISCUSSION
Five of the six mutations reported here are either
nonsense mutations creating premature stop codons, or
frameshift mutations that also lead to premature termina-
tion of translation. Four of these occur at codon 44 or
earlier; the fifth occurs at codon 343. Previously reported
nonsense mutations at codons 279, 347, 648, and 704 had
been expressed in Xenopus oocytes, and were found to lead
to loss of chloride channel function [2, 17]. Thus, these new
mutations cannot be polymorphisms, and can be presumed
also to inactivate the chloride channel. The sixth mutation,
S244L, has already been reported to occur in three other
families [2, 11, 18], and has been demonstrated not to occur
in 110 chromosomes from unrelated individuals [2]. Ex-
pression of this missense mutation in Xenopus yields chlo-
ride currents that are markedly reduced, though detectable
Fig. 2. (Left panel) Segregation of the W343X mutation with disease in Family C. The C-to-T transition creates a BfaI recognition site, and the
PCR-amplified exon (427 bp) is digested to two fragments (258 and 169 bp) with BfaI. Patient C-I-1 is a woman with nephrolithiasis who is heterozygous
for this nonsense mutation. (Right panel) Segregation of the single base deletion at codon 44 with disease in Family E. The deletion of a single adenine,
which leads to frameshift with premature termination of transcription, creates a BsrI restriction site. The PCR using primers flanking the exon 3 yield
a product of 260 bp in normal individuals, and digestion with BsrI produces two products of 126 and 134 bp size which overlap in a single band on this
2% agarose gel.
Fig. 3. Transition of C to T at codon 34 in patient B. The resulting TGA
nonsense codon leads to termination of transcription.
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[2]. In addition to the two families in which rickets was
prominent [2, 11], the S244L mutation was recently re-
ported in a large kindred with “X-linked renal failure
without X-linked recessive hypophosphatemic rickets” [18].
In most respects the patients studied here were typical of
X-linked nephrolithiasis or Dent’s disease. Presentation in
childhood with hematuria, proteinuria, mild polyuria, and
often nephrolithiasis was common. Extreme degrees of
LMW proteinuria were found in all affected males. Other
abnormalities of tubular function included aminoaciduria
and hyperuricosuria. Although hyperuricosuria had been
described in occasional cases of XRN or Dent’s disease
[5–7], frank hypouricemia was reported in none of the
previously reported cases but was present in patient E-II-1
in the present report. Severe renal insufficiency occurs in
adulthood in this disease, although reduction in creatinine
clearance rates can begin in childhood. In those patients in
whom measurements were available, serum levels of PTH
were usually near or below the lower limit of normal, even
in the presence of some renal insufficiency, and levels of
1,25-dihydroxyvitamin D were modestly elevated, as is
typical of this disease [1].
Female carriers of this recessive disease, who are het-
erozygous for the presence of a mutation in CLCN5,
typically have moderate degrees of LMW proteinuria and
may have hypercalciuria, but in previous reports lack any
clinical evidence of kidney stones, nephrocalcinosis, renal
failure, hematuria, or other symptomatic features [1, 6, 7].
Wrong, Norden and Feest reported a history of a 59-year-
old woman in one family with Dent’s disease who was said
to have had renal failure and nephrocalcinosis, but muta-
tion analysis could not be performed in that woman be-
cause she had died in 1965 [7]. The families in the present
report are therefore remarkable in that three of the het-
erozygous females have symptomatic disease. Women with
symptomatic nephrolithiasis include patient C-I-1, who is
heterozygous for the W343X mutation, and patient A-I-1,
who is heterozygous for the R28X mutation. In addition,
Fig. 4. Cleavase® fragment length polymorphism (CFLP) analyses. (Left panel) Deletion of A at codon 40 in exon 3 alters pattern of bands on CFLP
analysis in patients D-II-1 (lane 1) and D-II-2 (lane 2) as compared with the normal pattern in lanes 4, 5, and 6. The exon in the patient represented
in lane 6 was confirmed to be normal by sequencing. Patient E-II-1, with a different mutation in the same exon (deletion of A at codon 44), is represented
in lane 3, where the pattern of bands differs as well. (Right panel) C-to-T transition at codon 244 in exon 7 in patient F (lane 1) alters the band indicated
by the arrow as compared with normal samples in lanes 2, 3, and 4.
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patient A-I-2 has moderate renal insufficiency and protein-
uria, although the presence of hypertension and the ab-
sence of nephrocalcinosis indicate the possibility that this
patient had hypertensive nephropathy. While these women
were not tested for the presence of a second mutation on
their other X chromosome, patients C-I-1 (Fig. 2) and
A-I-2 (not shown) have had normal sons, and thus can be
presumed to carry a normal copy of the CLCN5 gene.
Rickets or osteomalacia is present in a minority of
patients with this disease, although two families have been
reported in which rickets was the dominant clinical feature
in all affected boys [10, 11]. It is notable that the mutation
present in both of those families (S244L) was also present
in our patient F, who lacked any evidence of bone disease.
By history none of the other three affected males in his
family had had rickets either. This series also includes
patient B, with the R34X mutation, who had symptomatic
rickets at age two years. This nonsense mutation leads to
termination of transcription very early in the sequence:
codon 34 in a protein with 746 amino acids. In previously
described families with nonsense mutations, and in the
family with a complete deletion of the CLCN5 gene, only 4
of a total of 16 affected males were reported to have
rickets, and the nature of the mutation appears to offer no
clue as to the occurrence of rickets. Figure 5 represents a
summary of those mutations identified to date.
These studies expand the range of mutations identified in
this disease, and broaden the phenotypic range to include
clinically affected women and the first North American
case with severe rickets.
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Fig. 5. Schematic summary of the amino acid sequence of the CLC-5 channel protein with predicted topology, revised from Lloyd et al [2] to indicate
27 mutations reported so far ([2–4, 8, 9, 11, 17, 18], and this report). These include 10 missense, 7 nonsense, and 6 frameshift mutations, in addition
to 2 splice-site mutations, one intragenic deletion, and one in-frame insertion of a triplet encoding histidine. Not shown are two deletions of 515 kb [19]
and 180 kb [9] encompassing the entire gene, so that a total of 29 mutations have been reported to date. The six mutations in the current report are
indicated with asterisks (*), including S244L and W343X which had previously been reported in other families [2, 3, 11, 18].
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